• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …

Importance Determining psoriasis prevalence is fundamental to understanding the burden of
the disease, the populations most affected, and health policies to address the disease …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The
treatment of PsA has changed substantially over the past 10 years. Clinical practice …

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …

Psoriasis is a chronic inflammatory skin disease that affects 2% to 3% of the US population.
The immune response in psoriasis includes enhanced activation of T cells and myeloid …

Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities
in addition to the characteristic skin lesions. Metabolic syndrome (MetS) is the most frequent …

Importance Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to
psoriatic inflammation. Objective To evaluate the efficacy and safety of risankizumab vs …